Peak HumanDatabase
    All Research
    PAPER PTAU21Diagnostic Study

    Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison

    Head-to-head comparison of plasma p-tau217 assays; both distinguished Alzheimer's disease from other neurodegenerative diseases with high accuracy (AUC approximately 0.95).

    Evidence

    7/10

    Moderate Evidence

    Sample

    —

    subjects

    Duration

    —

    study period

    Journal

    —

    02

    Key Findings

    1. 01

      Plasma p-tau217 discriminated AD from non-AD neurodegeneration with AUC ~0.95

    2. 02

      Lumipulse and ALZpath SIMOA assays performed comparably

    03

    Structured Methods

    Study Design
    Diagnostic Study
    Sample Size
    Not reported
    Study Duration
    Not reported
    Methodology
    Not reported
    Limitations
    Not reported
    04

    Citations & References

    Cite this paper

    Unknown authors (n.d.). Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.

    Source

    Publisher

    05

    Indexing

    Topics

    Alzheimer'sblood biomarker

    Biomarkers

    p-Tau 217p-Tau 181
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation
    See your Peak Human Score How it works